Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1007/s00467-016-3495-1

http://scihub22266oqcxt.onion/10.1007/s00467-016-3495-1
suck pdf from google scholar
C5915370!5915370 !27704256
unlimited free pdf from europmc27704256
    free
PDF from PMC    free
html from PMC    free

Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27704256 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215

suck abstract from ncbi

pmid27704256
      Pediatr+Nephrol 2017 ; 32 (2 ): 321-330
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Achieving remission of proteinuria in childhood CKD #MMPMID27704256
  • Ruggenenti P ; Cravedi P ; Chianca A ; Caruso M ; Remuzzi G
  • Pediatr Nephrol 2017[Feb]; 32 (2 ): 321-330 PMID27704256 show ga
  • BACKGROUND: A multidrug treatment strategy that targets urinary proteins with an angiotensin-converting enzyme (ACE) inhibitor and angiotensin receptor blocker (ARB) up-titrated to the respective maximum tolerated dose combined with intensified blood pressure (BP) control has been found to prevent renal function loss in adults with proteinuric nephropathies. Herein, we investigated the effects of this treatment protocol in the pediatric patient population. METHODS: From May 2002 to September 2014 we included in this observational, longitudinal, cohort study 20 consecutive children with chronic nephropathies and 24-h proteinuria of >200 mg who had received ramipril and losartan up-titrated to the respective maximum approved and tolerated doses [mean (?standard deviation) dose:2.48?(1.37) mg/m(2) and 0.61 (0.46) mg/kg daily, respectively]. The primary efficacy endpoint was a >50 % reduction in 24-h proteinuria to <200 mg (remission). Secondary outcomes included changes in proteinuria, serum albumin, BP, and glomerular filtration rate (GFR). RESULTS: Mean (± standard deviation) patient age at inclusion was 13.8?±?2.8 years, and the median [interquartile range (IQR)] serum creatinine level and proteinuria were 0.7 (0.6-1.0) mg/dl and 690 (379-1270) mg/24 h or 435 (252-711) mg/m(2)/24 h, respectively. Proteinuria significantly decreased by month 6 of follow-up, and serum albumin levels increased over a median follow-up period of 78 (IQR 39-105) months. In the nine children who achieved remission, proteinuria reduction persisted throughout the whole follow-up without rebounds. The GFR improved in those children who achieved remission and worsened in those who did not. The mean GFR slopes differed significantly between these two groups (p?
  • |Adolescent [MESH]
  • |Angiotensin Receptor Antagonists/*administration & dosage [MESH]
  • |Angiotensin-Converting Enzyme Inhibitors/*administration & dosage [MESH]
  • |Blood Pressure/drug effects [MESH]
  • |Child [MESH]
  • |Drug Therapy, Combination [MESH]
  • |Female [MESH]
  • |Humans [MESH]
  • |Longitudinal Studies [MESH]
  • |Losartan/*administration & dosage [MESH]
  • |Male [MESH]
  • |Maximum Tolerated Dose [MESH]
  • |Proteinuria/*drug therapy [MESH]
  • |Ramipril/*administration & dosage [MESH]
  • |Renal Insufficiency, Chronic/*drug therapy [MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box